Adlai NortyeFrom Adlai's website (emphasis mine). If this is true then it will be about $80 million upfront to ONC, if I remember correctly. Perhaps someone can confirm the payment.
https://en.adlainortye.com/index.php/product_info?id=3
Phase II studies have shown an approximate doubling of OS in HR+/HER2-mBC patients who received AN1004. We received the approval from the NMPA in February 2019 for our initiation of an open-label, randomized, multi-center, Phase III clinical trial for AN1004 in combination with paclitaxel in patients with HR+/HER2-mBC. We initiated a bridging trial in China in March 2021 to assess the safety and tolerability of AN1004 in combination with paclitaxel for the Chinese patient population with HR+/HER2- mBC. We plan to initiate Phase III clinical trials in China in the first half of 2022.